Search
  • Search


    Radioactive seeds for localizing breast cancer

    HUS-yhtymä

    Radioactive seeds for localizing breast cancer

    1. Competition notice published

      Feb 3, 10:31 AMFebruary 3, 2026 10:31 AM
    2. Contract signed

      May 18, 12:00 AMMay 18, 2026 12:00 AM
    3. Contract start date

      May 27, 12:00 AMMay 27, 2026 12:00 AM
    4. Result notice published

      Sep 23, 3:33 AMSeptember 23, 2026 3:33 AM

    Brief

    Finland: Tenders/HUS-yhtymä/Radioactive seeds for localizing breast cancer

    Awarded

    The competition has ended and a winner has been selected.

    Award
    Price only
    Procedure
    OpenSingle stage
    Agreement
    Buying goodsover 4 years

    Brief

    HUS Group has entered into an agreement with MoMedico ApS and BXTAccelyon Ltd for the delivery of radioactive seeds for localizing breast cancer in Finland. The contract has a duration of 2+1+1 years, with an estimated total maximum value of 1,100,000 EUR. The procurement was divided into four lots, covering seeds and needles separately or preloaded, with activities of 0.1 mCi or 0.2 mCi. The award criteria was based on the lowest price.

    Result

    TED
    • BXTAccelyon Ltd
      Winner
    • MoMedico ApS
      Winner
    • Number of bids
      3
    • Contract value
      €1,100,000

    Custom Assessment Criteria

    • Get answers to your bid/no-bid criteria

      Set them up once and Cobrief answers them in every tender

    Will you bid?

    The agent sets up the bid and writes the first draft. Free for 14 days.

    Award Criteria

    • Description

      Kaikissa hankinnan osissa oli valintaperusteena kokonaistaloudellinen edullisuus, halvin hinta.

      Source

      No source found in the documents. Check the weight against the tender documents.

    Previous winners

    • Who are you up against?

      The suppliers who have won similar contracts at HUS-yhtymä

    From the notice

    • The HUS Group requests tenders for radioactive seeds for localizing breast cancer. The procurement includes the products that are described in more detail in Annex 1 Product and Price Form. The tenderer must enter the product details and offered prices in Annex 1 Product and Price Form. The procurement is divided into lots, as follows: 1. Seeds and needles separately, activity 0.1 mCi 2. Seeds and needles separately, activity 0.2 mCi 3. Seeds preloaded in the needle, activity 0.1 mCi 4. Seeds preloaded in the needle, activity 0.2 mCi The tenderers may leave a tender to one or more lots as they decide. The goal of this competitive procurement is to get products that are safe to use and serve the intended purpose. The goal is also to have good product delivery reliability and to have products available when they are needed. The subject matter of the procurement also includes additional products related to the products tendered, such as additional sizes and accessories, which are indicated in Annex 1 Product and Price Form. In addition, during the contract period, products belonging to the product groups that are the subject of the contract, may be acquired in accordance with the estimated value of the contract, also when they are not specified in the product annex (please see draft agreement). The agreement period is two (2) years. It may be extended by an option period of 1 + 1 years. The total estimated value of the procurement (VAT 0%) is approximately EUR 900 000 -1 100 000. This is an estimate and the contracting entity does not commit neither to the stated euro amounts and nor the consumption figures indicated in the invitation to tender. The final order quantities may be higher or lower than stated. The subject matter and requirements of the procurement are described in detail in the invitation to tender and its annexes.Main features of the procedureThe procurement shall comply with the Act on Public Procurement and Concession Contracts (1397/2016, referred to as the Public Procurement Act). The procurement value exceeds the EU threshold value. The procedure shall be an open procedure as defined in section 32 of the Public Procurement Act. PROCESSING OF TENDERS The procedure shall include the following phases: Contracting entity 1. Opens the tenders 2. Verifies the suitability of the tenderer 3. Checks that the tenders conform to the invitation to tender 4. Conducts possible trial use 5. Compares the tenders 6. Makes a procurement decision and communicates it to all the tenderers 7. Requests and checks certificates and reports on the suitability of the winning tenderer(s) 8. Concludes an agreement with the selected tenderer(s) LANGUAGE OF THE COMPETITIVE TENDERING PROCEDURE The procurement documents are available in English. If a tenderer needs the documents in another language, the tenderer shall be responsible for translation and liable for the associated costs. Tenders must be prepared in English. PARALLEL TENDERS Parallel tenders are not permitted.

    • Contact

      HUS Procurement Serviceskilpailutus.tiimi@hus.fi
    • Type
      Result
    • Main code
      Medical equipments, pharmaceuticals and personal care products
      33000000
    • 33141326Radiology procedural needles33151400Radiotherapy supplies33696400Isotopic reagents

    Similar active competitions

    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      Request for information: Radioactive seeds (I-125) and plaques (Ru-106) used in eye brachytherapy

      HUS Group is planning the procurement of radioactive products, specifically Iodine-125 (I-125) brachytherapy seeds and Ruthenium-106 (Ru-106) eye plaques/applicators, along with related accessories for the treatment of epibulbar and intraocular tumors. Suppliers are asked to provide information on their product portfolios, typical delivery times, and available options for accessories, quality assurance, and treatment planning systems by submitting their responses via email to kilpailutus.tiimi@hus.fi. Eckert & Ziegler BEBIG GmbH likely has the contract today.

      Planning
      Jan 25, 2027(88 days)
    • HUS-yhtymä

      Laboratorie- og analyseutstyr

      MLPA-Based CNV Testing for BRCA1/BRCA2

      HUS Group, the joint authority for Helsinki and Uusimaa, needs an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licenses, and other components required for routine use and generation of reportable patient results. The contract period is 2 years, after which it continues indefinitely until terminated. The estimated annual consumption is approximately 1600 reportable patient samples, to be delivered to the HUSLAB Laboratory of Genetics in Helsinki-Uusimaa, Finland. The award criterion is the lowest total comparison price.

      Competition
      Nov 9, 2026(11 days)
    • Päijät-Hämeen hyvinvointialue

      Medisinsk og laboratorieutstyr

      Tietopyyntö: Gammadetektori

      Päijät-Hämeen hyvinvointialue suunnittelee gammadetektorin hankintaa rintasyöpäleikkauksia varten, ja laitteen avulla paikannetaan imusolmukkeet, joihin radioaktiivinen merkkiaine on kulkeutunut. Hankinnan kohteena on langaton gammadetektori, jossa on langaton käsiosa paremman steriliteetin takaamiseksi leikkauksessa. Ostaja pyytää tietoa alalla toimivilta toimittajilta ja markkinoilla saatavilla olevista ratkaisuista markkinakartoituksen yhteydessä.

      Planning